Clinical trials: Allogeneic Bone Marrow Transplantation
Myelodysplastic Syndromes
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS)…
- Trial name
- NCT04742634
- Testing
- DEC-C, MyeloSeq-HD
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Washington University School of Medicine
Acute Lymphoblastic Leukemia
Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients
Patients with newly diagnosed Acute lymphoblastic leukemia after providing consent, will be screened for eligibility. Eligible patients will be treated with Vincristine (1 mg/m2 at Day 1 and Day 8), Dexamethasone 24 mg/d day 1-15…
- Trial name
- NCT01015261
- Testing
- Bone Marrow Transplantation, Chemotherapy
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Tehran University of Medical Sciences
CMV Viremia, Immunosuppression-related Infectious Disease
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an apheresis from a compatible donor.
- Trial name
- NCT04018261
- Testing
- Activated T-Lymphocytes
- Where
- 7 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Banc de Sang i Teixits
Lymphoma, Myeloma
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high.
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Trial name
- NCT00578942
- Testing
- Campath Purged Non-myeloablative ASCT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- David Rizzieri, MD
Related Donors Donating PBSC to a Family Member, Healthy Donors
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies.
- Conditions
- Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT04762875
- Testing
- MGTA-145, Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Ensoma
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy
- Trial name
- FLAT-Auto (NCT03961919)
- Testing
- Fludarabine, ARA-C, Treosulfan
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ciceri Fabio
Leukemia
Clofarabine Bone Marrow Cytoreduction
For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT.
- Trial name
- NCT00724009
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Chicago
Leukemia, Lymphoma
High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003116
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Acute Leukemia, Acute Lymphoblastic Leukemia
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT03970096
- Testing
- Total-Body Irradiation, Thiotepa, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft Vs Host Disease
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC)…
- Trial name
- NCT00136903
- Testing
- Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- Mesoblast, Inc.
GVHD,Acute, Acute Leukemia
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin [ATG]) will help prevent the…
- Conditions
- GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT06315309
- Testing
- ATG Combined with Tacrolimus and Mini Methotrexate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06287944
- Testing
- Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Allogeneic Blood and Marrow Transplantation (BMT), Graft Versus Host Disease
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention
Bone marrow transplantation (BMT) is used to successfully treat high-risk forms of leukemia, lymphoma, and other childhood cancers that were once considered incurable.
- Trial name
- NCT01487577
- Testing
- Mycophenolate mofetil
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pittsburgh
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary…
- Conditions
- Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
- Trial name
- NCT00029328
- Testing
- etanercept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- FDA Office of Orphan Products Development
Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL)
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT04872595
- Testing
- Personalized rATG (P-rATG), Hyper fractionated total body irradiation, Thiotepa
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or…
- Trial name
- NCT04429191
- Testing
- Humanized anti-CD117 Monoclonal Antibody (JSP191)
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jasper Therapeutics, Inc.
Myeloma, Plasma-Cell, Lymphoma, Malignant
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
The purpose of this study is to determine whether a less-intensive preparative therapy followed by an allogeneic peripheral stem cell transplantation will provide an effective treatment for your disease and whether it will be…
- Conditions
- Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes
- Trial name
- NCT00146055
- Testing
- Reduced intensity conditioning with allogeneic transplant
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lymphoma, Infection
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)
The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients.
- Conditions
- Lymphoma, Infection, Leukemia
- Trial name
- NCT00075803
- Testing
- Fluconazole, Voriconazole
- Where
- 33 sites in United States
- Volunteers
- 600 people
- Sponsor
- Medical College of Wisconsin